Oral Mucositis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Oral Mucositis (OM), also called stomatitis, is the most common, debilitating complication of cancer chemotherapy and radiotherapy, characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment. Typical manifestations of Oral Mucositis are varying degrees of erythema, atrophy, ulceration, and mucosa swelling. It has a significant negative impact on patients’ quality of life (QOL). Potential complications of OM include pain, increased the risk of local and systemic infections, bleeding, insufficient food intake, delays in the administration of radiotherapy and or chemotherapy, a dose reduction of the chemotherapy drugs, increased the length of hospital stays, associated economic burdens and in some cases life-threatening infections (septicemia in neutropenic instances). Mucositis is one of the most generally reported toxicities of mTOR inhibitors, and in some studies, it was the dose-limiting toxicity. Oral toxicities with other targeted agents, such as kinase inhibitors and monoclonal antibodies, are less common. Yet studies have shown a significant incidence of all-grade mucositis with bevacizumab, erlotinib, sorafenib, and sunitinib.

  • The incidence of oral toxicity associated with targeted agents has been shown to increase as the dose increases. The incidence of Oral Mucositis (OM) ranges from 590 to 650 cases per 100,000 population in the USA.

Thelansis’s “Oral Mucositis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oral Mucositis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Oral Mucositis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Oral Mucositis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Oral Mucositis– Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033